MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ)
(“MediPharm Labs” or the “Company”) a global leader in specialized,
research-driven cannabis extraction, distillation, purification and
cannabinoid isolation, is pleased to announce the appointment
of Braden Fenske as Chief Strategy Officer effective April 29,
2019. In this newly created executive role, Mr. Fenske
will be responsible for advancing the Company’s strategic corporate
initiatives in collaboration with the Company’s executives and
operational teams across the company. Leveraging his extensive
relationships within the healthcare industry, Mr. Fenske will also
focus on accelerating domestic and global growth and expanding
strategic partnerships to create additional value and
opportunities for MediPharm Labs’ new products and growing
portfolio of cannabis and non-cannabis customers.
Mr. Fenske brings to the Company 20 years
of diverse and highly specialized experience within the global
healthcare industry and prior to that the adult beverage
industry. Over a 15-year career with the Johnson & Johnson
Group of Companies (“J&J”), Mr. Fenske has developed unique and
extensive experience within the pharmaceutical and medical device
sectors leading product development, marketing, global strategy and
operations that spanned multiple therapeutic areas in the U.S.
and among global healthcare markets. Most recently, Mr. Fenske
served as Group Product Director, Global Strategic Marketing for
Biosense Webster Inc., a J&J Company. He managed J&J’s
Medical Devices’ “next billion-dollar new product launch” upon its
FDA approval in the USA and CE mark in Europe. Mr. Fenske’s
previous experience with Mark Anthony Brands Inc. and Molson Coors
Brewing Co. also provides unique insights into the recreational
consumer and the burgeoning edibles and cannabis based derivative
product segments.
“We are thrilled to have Braden join our team at
this pivotal moment in our history. With our leading extraction
industry performance and momentum, our expanding portfolio of
products, increasing customer base and deep pipeline of growth
opportunities, we have demonstrated a clear potential for
accelerated revenue growth,” said Patrick McCutcheon, Chief
Executive Officer, MediPharm Labs. “Braden’s proven record of
success developing operational growth strategies, his unique
understanding of the pharmaceutical and medical delivery systems
industry, and his U.S. and worldwide healthcare relationships, will
strengthen MediPharm Labs’ position as a trusted partner for
customers, and clinical trials, as we remain at the leading
edge of the industry and achieve our growth potential in this
rapidly evolving market.”
“I am excited to be joining the MediPharm Labs’
team positioned at the forefront of this quickly evolving industry
with demand for purified concentrates driving growth and
innovation,” said Braden Fenske, Chief Strategy Officer, MediPharm
Labs. “I have been impressed by the depth and caliber of the
talented management team, and the Company’s compelling platform to
be the dominant provider of scaled cannabinoid based derivative
products for medical and recreational consumers globally. I look
forward to working alongside these outstanding leaders to elevate
MediPharm Labs’ position as a trusted partner and deliver our next
stage of exponential growth.”
About Braden Fenske, Chief Strategy
Officer
Braden joins MediPharm Labs from Johnson &
Johnson Group of Companies, bringing over 20 years of experience in
diverse strategic, commercial, new product planning, and business
development roles predominantly in Pharmaceuticals and Medical
Devices industries.
Most recently, Braden served as Group Product
Director, Global Strategic Marketing for Biosense Webster Inc., a
J&J Company, with more than 1,300 professionals in 40 countries
around the world, recognized worldwide as a leader in the science
behind the diagnosis and treatment of cardiac arrhythmias. At
Biosense Webster, he led the strategy and execution of J&J’s
“most important New Product launch in the last decade” and
facilitated product development from Research & Development
through to commercial launch.
In his 15-year career with J&J in Canada and
the USA (J&J Medical Devices, Biosense Webster Inc., Janssen
Inc.), Braden held progressive roles on an accelerated leadership
path and was highly awarded with multiple wins in President’s &
Performance Clubs, Standards of Leadership and President’s
Innovation.
During his tenure with J&J, Braden also led
various global marketing initiatives for medical devices, driving
corporate strategy and innovative product launches to optimize
market share and revenue. Earlier in his career, Braden worked at
both Mark Anthony Brands Inc. and Molson Coors Brewing Co. with
leadership development roles in sales, marketing and trade
promotions. Braden holds a Bachelor of Commerce degree from the
University of Alberta.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the
distinction of being the first company in Canada to become a
licensed producer for cannabis oil production under the ACMPR
without first receiving a cannabis cultivation licence. This expert
focus on cannabis concentrates from our cGMP (current Good
Manufacturing Practices) and ISO standard clean rooms and critical
environments laboratory, allows MediPharm Labs to produce purified,
pharmaceutical-like cannabis oil and concentrates for advanced
derivative products. MediPharm Labs has invested in an expert,
research-driven team, state-of-the-art technology, downstream
extraction methodologies and purpose-built facilities to deliver
pure, safe and precisely-dosed cannabis products to patients and
consumers. MediPharm Labs’ private label program is a high margin
business for the Company, whereby it opportunistically procures dry
cannabis flower and trim from its numerous product supply partners,
to produce proprietary cannabis oil concentrate products for resale
globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia
Pty. Ltd., MediPharm Labs has also completed its application
process with the federal Office of Drug Control to extract and
import medical cannabis products in Australia.
For further information, please
contact: Investor Relations &
Communications Telephone: 705-719-7425 ext 216 Email:
investors@medipharmlabs.com Website:
www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning of the applicable
Canadian securities legislation. All statements, other than
statements of historical fact, are forward-looking statements and
are based on expectations, estimates and projections as at the date
of this news release. Any statement that involves discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as “expects”, or “does not expect”,
“is expected”, “anticipates” or “does not anticipate”, “plans”,
“budget”, “scheduled”, “forecasts”, “estimates”, “believes” or
“intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”,
“might” or “will” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, statements regarding an expanding portfolio
of products, accelerating domestic and global growth, expanding key
strategic partnerships, a growing portfolio of cannabis and
non-cannabis customers, an increasing customer base, a deep
pipeline of growth opportunities, accelerated revenue growth,
GMP certification, and the establishment of operations in
Australia. Forward-looking statements are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm Labs to obtain
adequate financing; the delay or failure to receive regulatory
approvals: and other factors discussed in the Company’s filings,
available on the SEDAR website at www.sedar.com. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, MediPharm Labs assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change.
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024